|

Role of Eplerenone in Reducing Recurrence of Atrial Fibrillation in Patients With Structural Heart Disease

RECRUITINGPhase 1Sponsored by Assiut University
Actively Recruiting
PhasePhase 1
SponsorAssiut University
Started2024-08-10
Est. completion2024-08-13
Eligibility
Age20 Years – 70 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06556732

Summary

This is a prospective comparative study, conducted at Cardiology Department, Aswan University Hospital on AF patients with structural heart disease. Eplerenone 25 mg daily will be given and searching for AF recurrence among study population.

Eligibility

Age: 20 Years – 70 YearsHealthy volunteers accepted
Inclusion Criteria:

* Patients with non-valvular AF who underwent cardioversion to sinus rhythm either medical, electrical or even spontaneously

Exclusion Criteria:

* Patients with rheumatic heart disease.
* Thyroid dysfunction.
* Wolf-Parkinson-White (WPW) syndrome.
* Renal impairment.
* Hyperkalemia.
* Acute coronary syndrome.
* Pregnancy.
* Left ventricular (LV) dysfunction with ejection fraction (EF) less than 40%.
* On current use of eplerenone.

Conditions2

Atrial FibrillationHeart Disease

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.